Download PDF
Pneumologie 2023; 77(07): 435-439
DOI: 10.1055/a-2022-4044
Schritt für Schritt

High-Flow-Sauerstofftherapie – Schritt für Schritt

Tim Tristan Hardel
,
Jörn Grensemann
,
Stefan Kluge
› Further Information
Also available at
    Permissions and Reprints

In den letzten Jahren hat sich die High-Flow-Sauerstofftherapie (HFNC) auf den meisten Intensivstationen als Oxygenierungsmethode bei respiratorisch stark eingeschränkten Patienten etabliert und bewährt. Vorteile dieses Verfahrens, das insbesondere bei Patienten mit einer Hypoxämie eingesetzt wird, sind die einfache Applikation und die gute Toleranz durch den Patienten.

Publication History

Article published online:
13 July 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Simon M, Grensemann J, Kluge S. High-Flow-Sauerstofftherapie in der Intensivmedizin. Journal Club AINS 2018; 7: 106-116
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Sztrymf B, Messika J, Bertrand F. et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med 2011; 37: 1780-1786 DOI: 10.1007/s00134-011-2354-6. (PMID: 21946925)
    CrossrefPubMedGoogle Scholar
  • 3 Luo JC, Lu MS, Zhao ZH. et al. Positive end-expiratory pressure effect of 3 high-flow nasal cannula devices. Respir Care 2017; 62: 888-895 DOI: 10.4187/respcare.05337. (PMID: 28442633)
    CrossrefPubMedGoogle Scholar
  • 4 Besnier E, Hobeika S, NSeir S. et al. High-flow nasal cannula therapy: clinical practice in intensive care units. Ann Intensive Care 2019; 9: 98 DOI: 10.1186/s13613-019-0569-9. (PMID: 31485841)
    CrossrefPubMedGoogle Scholar
  • 5 Rochwerg B, Granton D, Wang DX. et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med 2019; 45: 563-572
    CrossrefPubMedGoogle Scholar
  • 6 Grensemann J, Fuhrmann V, Kluge S. Oxygen treatment in intensive care and emergency medicine. Dtsch Arztebl Int 2018; 115: 455 DOI: 10.3238/arztebl.2018.0455. (PMID: 30064624)
    CrossrefPubMedGoogle Scholar
  • 7 Chu DK, Kim LH, Young PJ. et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-ana- lysis. Lancet 2018; 391: 1693-1705
    CrossrefPubMedGoogle Scholar
  • 8 Kotoda M, Hishiyama S, Mitsui K. et al. Assessment of the potential for pathogen dispersal during high-flow nasal therapy. J Hosp Infect 2020; 104: 534-537
    CrossrefPubMedGoogle Scholar
  • 9 Hui DS, Chow BK, Lo T. et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J 2019; 53: 1802339
    CrossrefPubMedGoogle Scholar
  • 10 Hui DS, Chow BK, Chu LCY. et al. Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest 2009; 135: 648-654
    CrossrefPubMedGoogle Scholar
  • 11 Ehrmann S, Li J, Ibarra-Estrada M. et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. The Lancet Respiratory Medicine 2021; 9: 1387-1395
    CrossrefPubMedGoogle Scholar